Lisocabtagene Maraleucel (liso-cel) Versus Standard of Care (SOC) with Salvage Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients with Relapsed or Refractory Large B-Cell Lymphoma (LBCL): Primary Analysis of the Randomized, Phase 3 Transform Study
Year: 2022
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Jeremy S. Abramson, Scott R. Solomon, Jon E. Arnason, Patrick B. Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew A. Lunning, Alessandro Crotta, Sandrine Montheard, Alessandro Previtali, Manali Kamdar
Institutions: Harvard University, Massachusetts General Hospital, Northside Hospital, Beth Israel Deaconess Medical Center, Mayo Clinic, Helios Hospital Berlin-Buch, University of Minnesota, OU Health Stephenson Cancer Center, Karolinska University Hospital, Karolinska Institutet, Erasmus MC, Roswell Park Comprehensive Cancer Center, National Cancer Centre Japan, Centre Hospitalier Universitaire de Lille, Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Nebraska at Omaha, Bristol-Myers Squibb (Switzerland), University of Colorado Cancer Center
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310118199